Posted by Michael Wonder on 04 Sep 2024
Zanubrutinib for the treatment of patients with marginal zone lymphoma after anti-CD20-based treatment
4 September 2024 - NICE has published final evidence-based recommendations on the use of zanubrutinib (Brukinsa) for the treatment of adults with marginal zone lymphoma after anti-CD20-based treatment.
Zanubrutinib is recommended as an option for the treatment of adults with marginal zone lymphoma who have had at least one anti‑CD20-based treatment. Zanubrutinib is only recommended if BeiGene provides it according to the commercial arrangement.
